Literature DB >> 28969618

Correction to: Tumor-suppressive effects of atelocollagen-conjugated hsa-miR-520d-5p on un-differentiated cancer cells in a mouse xenograft model.

Yoshitaka Ishihara1, Satoshi Tsuno1, Satoshi Kuwamoto2, Taro Yamashita3, Yusuke Endo1, Keigo Miura4, Yugo Miura5, Takemasa Sato6, Junichi Hasegawa1, Norimasa Miura7.   

Abstract

Entities:  

Year:  2017        PMID: 28969618      PMCID: PMC5625683          DOI: 10.1186/s12885-017-3653-2

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


× No keyword cloud information.

Correction

After publication of the original article [1] the authors found the following errors had occurred: The imaging photo was incorrectly selected for Fig. 4. The original article contains imaging relating to another series. An updated version of Fig. 4 is included with this Correction.
Fig. 4

The therapeutic effect of 520d-5p-conjugated atelocollagen on subcutaneously inoculated tumors as monitored by an in vivo imaging system. a A representative image of the therapeutic effect of 520d-5p/atelocollagen using an in vivo imaging system. At each inoculation site, 37.5% (3/8) of the tumors disappeared. The growth of tumors that received 520d-5p was significantly suppressed, and metastatic ability was entirely inhibited in the remaining mice. A time course (top) of 520d/HLF/GFP cells (520d-5p-transfected and GFP-expressing HLF) is depicted. Representative sequential images (bottom) of scrambled/HLF/GFP cells (scrambled-transfected GFP-expressing HLF). b In HMV-I tumors, 12.5% (1/8) of the tumors disappeared. After treatment with 520d-5p, the growth of other tumors was significantly suppressed, and their metastatic ability was entirely inhibited. 520d/HMV-I/GFP and scrambled/HMV-I/GFP indicate 520d-5p-transfected, GFP-expressing HLF (top) and scramble-transfected, GFP-expressing HMV-I (bottom), respectively

In the original Fig. 5b figure legend, reference is made to an HE stain, however this has been made incorrectly. All references to an HE stain should therefore be omitted. The entirety of Figure legend 5b is included below, with the amendments made to the first sentence (which is included in bold for reference):
Fig. 5

Evidence of human genomic DNA at the injection site. a miR-520d-5p expression was examined in HLF (n = 5) and HMV-I (n = 7) tumors resected after 520d/atelocollagen treatment. 520d/HMV-I tumors significantly expressed 520d-5p (*, P < 0.05), and 520d/HLF tumors tended to express miR-520d-5p (P = 0.051). scram.: scrambled. b Microscopic examination of HLF (left; ×100 magnification) and HMV-I tumors (right; ×200 magnification) that displayed suppressed tumor growth. HLF tumors treated with 520d/atelocollagen exhibited GFP-expressing muscle tissues, including undifferentiated tumor cells unaccompanied by necrosis. HMV-I tumors treated with 520d/atelocollagen showed undifferentiated neoplastic cells. This finding is not inconsistent, as malignant melanomas are observed to be accompanied by extensive necrosis, as shown around A. c Histological findings in the area where there should have been a tumor are presented (HE stain, ×40 magnification). The area of the HLF tumors that disappeared is surrounded by an oval (left top). GFP expression was confirmed (left bottom). Histological findings in the disappearance site of HMV-I tumors showed no malignant cells. This finding was similar to that for 520d–treated HLF tumors (HE stain, ×200 magnification) (right top), but we observed GFP even in the connective tissue (right bottom). We did not observe any malignant cells in the injection sites of mice in either case. d Fluorescence (F) (top) and a quantitative calibration line (bottom) in quantitative Alu-PCR. P.C. (left arrow) indicates a representative positive control (a subcutaneous tumor generated from mock/HLF cells). The reaction of interest was performed using DNA from the scar-like area of cases (C; right arrow) to confirm that human genomic material was present in the injection site. The average amount of human genomic DNA derived from human hepatoma (mock/HLF: n = 3) was approximately 50 ng. Case (C) showed 55.0 pg. The genome copy number was calculated based on the fact that 1 pg corresponds to approximately 0.333 human genome copies. Correlation coefficient, r = −0.996

The therapeutic effect of 520d-5p-conjugated atelocollagen on subcutaneously inoculated tumors as monitored by an in vivo imaging system. a A representative image of the therapeutic effect of 520d-5p/atelocollagen using an in vivo imaging system. At each inoculation site, 37.5% (3/8) of the tumors disappeared. The growth of tumors that received 520d-5p was significantly suppressed, and metastatic ability was entirely inhibited in the remaining mice. A time course (top) of 520d/HLF/GFP cells (520d-5p-transfected and GFP-expressing HLF) is depicted. Representative sequential images (bottom) of scrambled/HLF/GFP cells (scrambled-transfected GFP-expressing HLF). b In HMV-I tumors, 12.5% (1/8) of the tumors disappeared. After treatment with 520d-5p, the growth of other tumors was significantly suppressed, and their metastatic ability was entirely inhibited. 520d/HMV-I/GFP and scrambled/HMV-I/GFP indicate 520d-5p-transfected, GFP-expressing HLF (top) and scramble-transfected, GFP-expressing HMV-I (bottom), respectively Evidence of human genomic DNA at the injection site. a miR-520d-5p expression was examined in HLF (n = 5) and HMV-I (n = 7) tumors resected after 520d/atelocollagen treatment. 520d/HMV-I tumors significantly expressed 520d-5p (*, P < 0.05), and 520d/HLF tumors tended to express miR-520d-5p (P = 0.051). scram.: scrambled. b Microscopic examination of HLF (left; ×100 magnification) and HMV-I tumors (right; ×200 magnification) that displayed suppressed tumor growth. HLF tumors treated with 520d/atelocollagen exhibited GFP-expressing muscle tissues, including undifferentiated tumor cells unaccompanied by necrosis. HMV-I tumors treated with 520d/atelocollagen showed undifferentiated neoplastic cells. This finding is not inconsistent, as malignant melanomas are observed to be accompanied by extensive necrosis, as shown around A. c Histological findings in the area where there should have been a tumor are presented (HE stain, ×40 magnification). The area of the HLF tumors that disappeared is surrounded by an oval (left top). GFP expression was confirmed (left bottom). Histological findings in the disappearance site of HMV-I tumors showed no malignant cells. This finding was similar to that for 520d–treated HLF tumors (HE stain, ×200 magnification) (right top), but we observed GFP even in the connective tissue (right bottom). We did not observe any malignant cells in the injection sites of mice in either case. d Fluorescence (F) (top) and a quantitative calibration line (bottom) in quantitative Alu-PCR. P.C. (left arrow) indicates a representative positive control (a subcutaneous tumor generated from mock/HLF cells). The reaction of interest was performed using DNA from the scar-like area of cases (C; right arrow) to confirm that human genomic material was present in the injection site. The average amount of human genomic DNA derived from human hepatoma (mock/HLF: n = 3) was approximately 50 ng. Case (C) showed 55.0 pg. The genome copy number was calculated based on the fact that 1 pg corresponds to approximately 0.333 human genome copies. Correlation coefficient, r = −0.996 Figure legend 5b: Microscopic examination of HLF (left; ×100 magnification) and HMV-I tumors ( ; ×200 magnification) that displayed suppressed tumor growth. HLF tumors treated with 520d/atelocollagen exhibited GFP-expressing muscle tissues, including undifferentiated tumor cells unaccompanied by necrosis. HMV-I tumors treated with 520d/atelocollagen showed undifferentiated neoplastic cells. This finding is not inconsistent, as malignant melanomas are observed to be accompanied by extensive necrosis, as shown around A. A corrected version of Fig. 5 is included with this Correction.
  1 in total

1.  Tumor-suppressive effects of atelocollagen-conjugated hsa-miR-520d-5p on un-differentiated cancer cells in a mouse xenograft model.

Authors:  Yoshitaka Ishihara; Satoshi Tsuno; Satoshi Kuwamoto; Taro Yamashita; Yusuke Endo; Keigo Miura; Yugo Miura; Takemasa Sato; Junichi Hasegawa; Norimasa Miura
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.